-
公开(公告)号：EP4433160A1
公开(公告)日：2024-09-25
申请号：EP22840844.9
申请日：2022-11-16
发明人： MACDONALD, Brian , QUISEL, John , SAVAGE, Will , YANG, Hua , YU, Jonathan , WU, Min , BECONI, Maria , PEREZ, Jennifer, M. , MUELLER, Bernhard , POPP, Andreas
IPC分类号： A61P7/06 , C07K16/22 , C07K16/28 , A61K39/395
CPC分类号： A61K2039/50520130101 , C07K16/28 , C07K16/22 , C07K2317/7620130101 , A61P7/06 , C07K2317/2420130101 , A61K39/395
-
公开(公告)号：EP3636651A1
公开(公告)日：2020-04-15
申请号：EP19212082.2
申请日：2016-11-24
发明人： BACKFISCH, Gisela , BAKKER, Margaretha Henrica Maria , BLAICH, Günter , BRAJE, Wilfried , DRESCHER, Karla , ERHARD, Thomas , HAUPT, Andreas , HOFT, Carolin , LAKICS, Viktor , MACK, Helmut , OELLIEN, Frank , PETER, Raimund , RELO, Ana Lucia
IPC分类号： C07D498/04 , C07D498/14 , A61K31/553 , A61P25/24
摘要： The present invention relates to compound of formula (I)
wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor.-
公开(公告)号：EP3191471B1
公开(公告)日：2020-03-11
申请号：EP15762980.9
申请日：2015-09-10
发明人： AMBERG, Wilhelm , BREWER, Jason T. , HUTCHINS, Charles , LANGE, Udo , LAO, Yanbin , LI, Huan-Qiu , POHLKI, Frauke , VASUDEVAN, Anil , WANG, Ying , ZHAO, Hongyu
IPC分类号： C07D403/12
-
4.发明公开
公开(公告)号：EP3601255A1
公开(公告)日：2020-02-05
申请号：EP18716451.2
申请日：2018-03-20
发明人： BACKFISCH, Gisela , BAKKER, Margaretha , BLACK, Lawrence , BRAJE, Wilfried , DRESCHER, Karla , ERHARD, Thomas , HAUPT, Andreas , HOFT, Carolin , KLING, Andreas , LAKICS, Viktor , MACK, Helmut , RELO, Ana Lucia , OELLIEN, Frank
IPC分类号： C07D401/12 , C07D405/12 , C07D207/16 , A61P25/24 , A61P25/14 , A61P9/00 , A61P25/22 , A61P25/28 , A61P25/18 , A61P25/30 , A61P3/10 , A61K31/40
-
公开(公告)号：EP3535244A1
公开(公告)日：2019-09-11
申请号：EP17800433.9
申请日：2017-11-02
发明人： AMBERG, Wilhelm , VAN BERGEIJK, Jeroen , GENESTE, Herve , HORNBERGER, Wilfried , VAN DER KAM, Elizabeth Louise , LANGE, Udo , MEZLER, Mario , OCHSE, Michael , OELLIEN, Frank , WALLESER, Patrick , TURNER, Sean C
IPC分类号： C07D221/20 , C07D205/12 , C07D491/107 , A61K31/397 , A61K31/438 , A61P25/00
-
6.发明公开
公开(公告)号：EP3464372A1
公开(公告)日：2019-04-10
申请号：EP17731343.4
申请日：2017-05-31
-
7.发明公开
公开(公告)号：EP3369746A1
公开(公告)日：2018-09-05
申请号：EP18166632.2
申请日：2013-01-25
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/68 , C07B59/00 , A61K49/00 , C07K16/22 , A61K39/00 , A61K51/10
CPC分类号： C07K16/22 , A61K39/3955 , A61K49/0002 , A61K49/0058 , A61K51/1018 , A61K51/1021 , A61K2039/505 , C07B59/008 , C07B2200/05 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/76 , G01N33/6896 , G01N2333/705 , G01N2800/28 , G01N2800/285
摘要： Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
-
公开(公告)号：EP3353155A1
公开(公告)日：2018-08-01
申请号：EP16770000.4
申请日：2016-09-21
发明人： BACKFISCH, Gisela , BAKKER, Margaretha , BLAICH, Günter , BRAJE, Wilfried , DRESCHER, Karla , ERHARD, Thomas , HAUPT, Andreas , HOFT, Carolin , KLING, Andreas , LAKICS, Viktor , MACK, Helmut , OELLIEN, Frank , PETER, Raimund , POHLKI, Frauke , RELO, Ana Lucia
IPC分类号： C07D241/20 , C07D213/56 , A61K31/4439 , A61K31/497 , A61P25/00
CPC分类号： C07D213/56 , C07D241/20
摘要： The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl- bound N-amide moiety derived from an α-amino acid of formula I where the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, and to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT2C receptor.
-
公开(公告)号：EP2303242B1
公开(公告)日：2018-05-02
申请号：EP09772440.5
申请日：2009-06-30
CPC分类号： A61K47/32 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2095
摘要： A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95 % by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.
-
公开(公告)号：EP3309173A1
公开(公告)日：2018-04-18
申请号：EP17204022.2
申请日：2009-02-27
发明人： MÜLLER, Bernhard K. , SCHMIDT, Martin , BARLOW, Eve H. , LEDDY, Mary R. , HSIEH, Chung-Ming , BARDWELL, Phillip D.
IPC分类号： C07K16/22 , A61K39/395 , C07K16/28 , A61K39/00 , A61K45/06
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The subject invention relates to monoclonal antibodies which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or antigen binding fragments thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
摘要翻译： 本发明涉及结合并中和RGM A蛋白的单克隆抗体。 具体而言，这些抗体具有抑制RGM A与其受体和/或共同受体结合的能力。 本发明的这些抗体或其抗原结合片段可用于检测RGM A和用于抑制RGM A活性，例如在患有包括但不限于多发性硬化症，哺乳动物脑外伤，脊髓损伤，中风， 神经退行性疾病和精神分裂症。
-
-
-
-
-
-
-
-
-
搜索结果
150 条记录 (耗时 0.038 秒)
